Connect with us
Novartis plans to sell Morphosys' business, acquired for €2.7 billion in 2023, affecting 330 employees as it closes two factories by 2025. Initially aimed at boosting...
A U.S. judge ruled that Novartis lacked grounds to suspend the launch of MSN's generic version of Entresto but ordered a temporary production halt pending Novartis'...
Zolgensma, Novartis' gene therapy for SMA, remains the world's most expensive medicine, priced between $1.2 million and $2.1 million per dose. Despite its high cost, it's...
Novartis CEO said that the pharmaceutical company's strategy involves not exceeding acquisitions of more than $5 billion. The agreement with Cytokinetics meant a larger investment, since,...
The pharma sector faces a setback in sustainability, as AstraZeneca, Novartis, and Amgen, previously included in the Dow Jones Sustainability Index, are omitted in the latest...
Novartis has acquired global rights to develop, manufacture, and commercialize Leqvio under a licensing and collaboration agreement with Alnylam Pharmaceuticals, which is a leader in RNA...
Sandoz was spun off from Novartis on October 4th, following its listing on the Swiss SIX stock exchange. Sandoz works with generic or biosimilar medicines with...
Novartis is aiming for its annual sales to grow in the high single digits this year when it previously estimated they would grow in the mid-single...
Novartis has stated that it is focused on five therapeutic areas, including cardiovascular, immunology, and neuroscience. By markets, the company has detailed that it plans to...
Thanks to this investment plan, Novartis Italia, which already achieved a turnover of €1.72 billion in 2022, €78 million of which was obtained through exports, further...